Unknown

Dataset Information

0

Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents in patients with multivessel coronary artery disease compared to coronary artery bypass surgery five-years after intervention.


ABSTRACT: Cost-effectiveness of percutaneous coronary intervention (PCI) using drug-eluting stents (DES), and coronary artery bypass surgery (CABG) was analyzed in patients with multivessel coronary artery disease over a 5-year follow-up.DES implantation reducing revascularization rate and associated costs might be attractive for health economics as compared to CABG.Consecutive patients with multivessel DES-PCI (n?=?114, 3.3?±?1.2 DES/patient) or CABG (n?=?85, 2.7?±?0.9 grafts/patient) were included prospectively. Primary endpoint was cost-benefit of multivessel DES-PCI over CABG, and the incremental cost-effectiveness ratio (ICER) was calculated. Secondary endpoint was the incidence of major adverse cardiac and cerebrovascular events (MACCE), including acute myocardial infarction (AMI), all-cause death, revascularization, and stroke.Despite multiple uses for DES, in-hospital costs were significantly less for PCI than CABG, with 4551 €/patient difference between the groups. At 5-years, the overall costs remained higher for CABG patients (mean difference 5400 € between groups). Cost-effectiveness planes including all patients or subgroups of elderly patients, diabetic patients, or Syntax score >32 indicated that CABG is a more effective, more costly treatment mode for multivessel disease. At the 5-year follow-up, a higher incidence of MACCE (37.7% vs. 25.8%; log rank P?=?0.048) and a trend towards more AMI/death/stroke (25.4% vs. 21.2%, log rank P?=?0.359) was observed in PCI as compared to CABG. ICER indicated 45615 € or 126683 € to prevent one MACCE or AMI/death/stroke if CABG is performed.Cost-effectiveness analysis of DES-PCI vs. CABG demonstrated that CABG is the most effective, but most costly, treatment for preventing MACCE in patients with multivessel disease.

SUBMITTER: Krenn L 

PROVIDER: S-EPMC4262069 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC3603704 | BioStudies
1000-01-01 | S-EPMC5800539 | BioStudies
2016-01-01 | S-EPMC5142519 | BioStudies
2015-01-01 | S-EPMC5473156 | BioStudies
1000-01-01 | S-EPMC6215652 | BioStudies
2017-01-01 | S-EPMC5662302 | BioStudies
2020-01-01 | S-EPMC6961598 | BioStudies
2017-01-01 | S-EPMC5642747 | BioStudies
| S-EPMC6839829 | BioStudies
1000-01-01 | S-EPMC5940397 | BioStudies